TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05247814

Intervention type: GENETIC
Intervention: Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism
Description: All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism

Intervention type: OTHER
Intervention: Adverse Drug Reaction detection
Description: During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment

Intervention type: OTHER
Intervention: Falls Efficacy Scale International (FES-I)
Description: The FES-I wil be obtained to estimate fear of falling
Study: NCT05672511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation Teaching Method
Description: Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory. The control group will not receive any simulation training. Both groups will be given a knowledge test after teaching with simulation. Students in both groups will fill out a form evaluating their skills in performing the steps of vaginal examination before each vaginal examination is performed on women in the clinic.
Study: NCT06114277

Intervention type: OTHER
Intervention: ETCO2 levels
Description: Intraoperative ETCO2 values between 26 and 35 in laparoscopic robotic prostatectomy patients were included in group 1.

Intervention type: OTHER
Intervention: Patients with high ETCO2 levels
Description: Intraoperative ETCO2 values between 36 and 45 in laparoscopic robotic prostatectomy patients were included in group 2.
Study: NCT05780255

Intervention type: DEVICE
Intervention: VV-ECMO
Description: veno-venous extracorporeal membrane oxygenation
Study: NCT05403320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous cuff pressure regulation
Description: Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 control device. It includes an automatic high-sensitive subglottic capnograph which measures every few minutes the carbon dioxide level in the subglottic space. If the level of carbon dioxide is above the threshold (established by animal studies) the system will increase the cuff pressure by a formula, if the level is below the threshold, the system will decrease the cuff pressure by 1 mmHg. Variations of cuff pressure are allowed only between pressure limits set by the user (minimum and maximum)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent cuff pressure regulation
Description: ET cuff pressure will be manually measured three times per day using a portable manometer, and kept constant within 20-30 cmH2O

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic subglottic secretion drainage
Description: Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 device control which provides continuous subglottic secretion drainage (two different suction lines) and venting/rinsing (a third dedicated line)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual subglottic secretion drainage
Description: Subglottic secretions will be manually drained with a 10 mL syringe, using the only dedicated lumen

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tracheobronchial colonization assessment
Description: Tracheal aspirate will be performed after intubation and after 72 hours for microbiological colture

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tracheobronchial colonization assessment
Description: Tracheal aspirate will be performed after intubation and after 72 hours for microbiological colture

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microaspiration assessment
Description: Tracheal aspirates will be performed 72 hours after intubation, and collected in a predefined study center to measure pepsin and salivary amylase

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microaspiration assessment
Description: Tracheal aspirates will be performed 72 hours after intubation, and collected in a predefined study center to measure pepsin and salivary amylase

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAP assessment
Description: Patients will be follow to detect clinical, radiological or microbiological signs of VAP. If suspected, a tracheal aspirate or a bronchoalveolar lavage is performed to confirm the diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VAP assessment
Description: Patients will be follow to detect clinical, radiological or microbiological signs of VAP. If suspected, a tracheal aspirate or a bronchoalveolar lavage is performed to confirm the diagnosis
Study: NCT05560373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A injection, operational treatment, the best basic treatment
Description: intramuscular

Intervention type: OTHER
Group type: OTHER
Intervention: operational treatment, the best basic treatment
Description: other

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A injection, interventional treatment, the best basic treatment
Description: intramuscular

Intervention type: OTHER
Group type: OTHER
Intervention: Interventional treatment, the best basic treatment
Description: other
Study: NCT05184673

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral and environmental
Description: These are all active comparator yoga sequences

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral and environmental
Description: These are all active comparator yoga sequences

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral and environmental
Description: These are all active comparator yoga sequences

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral and environmental
Description: These are all active comparator yoga sequences
Study: NCT05381142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Elinzanetant will be administered as a single dose on Study Day 1 and a multiple dose once daily for another 6 consecutive days on Study Day 8 to Study Day 13.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered the same as Elinzanetant (BAY3427080)
Study: NCT05664542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESPB (regional Block)
Description: ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine and dexmedetomidine
Description: 0.2 % ropivacaine and dexmedetomidine
Study: NCT06006234

Intervention type: OTHER
Intervention: questionnaire survey
Description: questionnaire survey
Study: NCT05636592

Intervention type: DRUG
Intervention: immunotherapy
Description: statin combined with immunotherapy
Study: NCT05355272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Description: recombinant human growth hormone (rhGH)
Study: NCT05003622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: oral capsule
Study: NCT04086082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Markerless Image Guidance
Description: Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
Study: NCT06144775

Intervention type: OTHER
Intervention: Kinematics measures
Description: In a single session each child will be video-recorded while performing simple and complex rhythmic actions of the upper limbs with a social partner. The presence of characteristic motor behaviors, practice errors, perseverations, and movement variability will be observed. The study involves the use of three blocks of tasks of the neuropsychological battery (NEPSY-II): Finger Tapping, Visuo-Motor Precision, and Manual Motor Sequences. The order within each block will be randomized.

Intervention type: OTHER
Intervention: Kinematics measures
Description: In a single session each child will be video-recorded while performing simple and complex rhythmic actions of the upper limbs with a social partner. The presence of characteristic motor behaviors, practice errors, perseverations, and movement variability will be observed. The study involves the use of three blocks of tasks of the neuropsychological battery (NEPSY-II): Finger Tapping, Visuo-Motor Precision, and Manual Motor Sequences. The order within each block will be randomized.
Study: NCT06025669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap restriction
Description: There are 2 interventions in the single-arm, that is, the nap rested condition and the nap restriction condition. The sequence of nap intervention followed randomization.
Study: NCT05699265

Intervention type: DIAGNOSTIC_TEST
Intervention: Measures of arterial stiffness and endothelial function
Description: baseline cMRI, vascular reactivity studies, and CPET

Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory blood pressure monitoring
Description: A manual blood pressure with a mercury sphygmomanometer will be performed in order to have an accurate baseline measurement. The SphygmoCor SCOR-PVx System (Atcor Medical, Syndey, Australia), previously validated in the young, will be used for the assessment of PWV (pulse wave velocity) and the Heart Rate Variability (HRV).

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing (CPET)
Description: Cardiopulmonary exercise testing will be performed, and the patients will have a baseline oxygen uptake at rest to determine the rates for testing. A 12 lead ECG, heart rate, a 12 lead rhythm strip, and a 6 lead rhythm strip will be recorded. Oxygen consumption and carbon dioxide production will be measured. Blood pressure will be measured. Perceived exertion will be obtained during each workload using the Borg Scale. The results for submaximal effort testing will be derived from completed maximal testing. The outcome measures will be obtained once the subject reaches anaerobic threshold.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum and urine biomarkers
Description: Clinical labs drawn will include plasma and urine globotriaosylsphingosine (lyso-Gb3), globotriaosylceramide (GL3), blood urea nitrogen, creatinine, cystatin C, urinalysis, urine protein, urine microalbumin and urine creatinine. Labs specific for this study will include N-acetyl-β-glucosaminidase, urine neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1). All data will be obtained at three different time intervals: enrollment, 1 year and 2 years.
Study: NCT04593862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: The intervention will be performed on a treadmill and will include a warm-up and cool-down at 50-60% and 40% of the VO2peak respectively, for up to five minutes. The HIIT protocol will be 4x4, which consists of four bouts of four minutes at a workload corresponding to vigorous intensity (75-95% of the baseline and 6-week VO2peak) alternating with three minutes of recovery intervals at 40% of the VO2peak. The exercise session will last 35 minutes and include 16 minutes of high intensity exercise.
Study: NCT06452576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Watch vibrates.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: constraint-induced movement therapy
Description: A splint or mitt is placed on the stronger, unaffected hand to encourage use of the affected upper limb in therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: constraint-induced movement therapy
Description: A splint or mitt is placed on the stronger, unaffected hand to encourage use of the affected upper limb in therapy.
Study: NCT06212726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InjureFree
Description: The InjureFree software is a commercialized injury incident management platform for organizations working in sports and athlete care and is focused on providing administrators and caregivers' technology to enhance coordination of care. InjureFree will be utilized to track concussion management and communication following SRRC at Buchholz and Gainesville High Schools. This will not modify the current standard of practice for healthcare delivery, it will only modify the communication between members of the concussion management team
Study: NCT06653387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGuard Prime 80cm stent system
Description: This study is single arm looking at the technical success of the CGuard Prime 80cm stent system when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
Study: NCT06651840

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar diathermy Standard technique.
Description: The bipolar technique for group A:~A bipolar with straight blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively.
Study: NCT04777435

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic orientation test for TMA
Description: Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.
Study: NCT06547658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouth closure
Description: Closing the mouth during sleep by applying pressure to the mentum until the teeth were in occlusion, without altering the head position.
Study: NCT04967079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg given orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib given orally, every two weeks followed by a one-week discontinuation cycle
Study: NCT04943081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Description: Percutaneous nephrolithotomy (PCNL) is a technique used to remove complex renal stones, or stones resistant to shockwave lithotripsy. A tube is placed through the incision in the kidney, under X-ray guidance, and renal stones are extracted by using nephroscope
Study: NCT05899881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Description: 10 weeks of Hatha yoga, once per week, 60 minutes per class
Study: NCT04869345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LARKSPUR
Description: This intervention used in our prior research consists of skills training exercises designed to increase the frequency of positive affect. The 6 week intervention (5 weeks of content plus one week of home practice) consists of five components: (1) Positive events and gratitude; (2) mindfulness; (3) reappraisal; (4) strength and goals; and(5) acts of kindness. Participants will have up to 8 weeks to complete this intervention.
Study: NCT05506176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0417
Description: dose of 750 mg SIM0417 with 100 mg ritonavir.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (tablet)
Study: NCT04972240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: customization of abutment
Description: we will customize abutment for every patient not ready made
Study: NCT06214247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wedge NC Scoring Balloon Dilatation Catheter
Description: During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Wedge NC Scoring Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoreflex Scoring Balloon Dilatation Catheter
Description: During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using a similar product on the market in the control group, subsequently completing the remaining procedure.
Study: NCT05396079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tahini and bread
Description: Fifthy grams of tahini with 2 slices of white bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: margarine, cheese and bread
Description: 46 g of margarine and 38 g of cheese with 2 slices of white bread
Study: NCT06365866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRAXX Esophageal Brachytherapy Applicator.
Description: The device is intended for use with a commercially available after loader during brachytherapy. The purpose of the device is to deliver a radioactive source to the esophagus. This device is sterile, disposable, and single-use.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Add-on of intraluminal brachytherapy
Description: Brachytherapy protocol starts within 12 weeks after EBRT. High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions will be delivered.
Study: NCT04977102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraocular caliper-assisted capsulotomy
Description: Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Verion navigation system-assisted capsulotomy
Description: Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
Study: NCT05767554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief modified behavioral activation
Description: The clinician will deliver psychoeducation about the nature of depression and the rationale behind the behavioral activation model (i.e. increasing level of activation can begin a positive feedback cycle of reward and improvements in mood state). Participants will be encouraged to add new, enjoyable activities to their daily schedules. Clinicians will emphasize the importance of novelty and increased engagement with the surrounding environment in the psychoeducational portion and in activity scheduling.
Study: NCT06651840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coblation technique.
Description: The coblation technique for group B:~An coblator with tonsillar blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively.
Study: NCT06654414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIDE QUIT
Description: This is an adapted behavioral intervention based on the integrated treatment for smoking cessation, anxiety, and depressed mood, known as QUIT, for persons with HIV. Through our treatment adaption process of QUIT (guided by Aim 1 and 2 data), PRIDE QUIT will be a Cognitive-Behavioral therapy-based intervention tailored for transgender and gender diverse (TGD) individuals, aimed at to helping participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance.~There will be three major assessments: baseline (T1), at the end of the intervention (T2), and a three-month follow-up visit (T3). This intervention group will likely receive 6-10 weekly sessions, with the quit day set around session 4-6. They will also receive transdermal nicotine patches (TNP) for a period of 8 weeks prior to the quit session.
Study: NCT05162027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe
Description: Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
Study: NCT05560542

Intervention type: DRUG
Group type: OTHER
Intervention: Atropine and Dexamethasone
Description: Intrathecal dexamethasone, atropine or their combination.

Intervention type: DRUG
Group type: OTHER
Intervention: Atropine and Dexamethasone
Description: Intrathecal dexamethasone, atropine or their combination.

Intervention type: DRUG
Group type: OTHER
Intervention: Atropine and Dexamethasone
Description: Intrathecal dexamethasone, atropine or their combination.
Study: NCT04672564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrimycin
Description: Carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given once-daily for 14 days (2 tablets) after a meal, if a patient experiences an eating problem, placebo will be taken without food.
Study: NCT05251740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Altimate Medical EasyStand Bantam
Description: The child will stand in the device for 60 min per day, 5 days per week for 2 months.
Study: NCT04750759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niclosamide + Camostat
Description: Niclosamide will be applied in combination with camostat.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to interventional drug
Study: NCT06401122

Intervention type: PROCEDURE
Intervention: haemodialysis
Description: process of filtering the blood of a person whose kidneys are not working normally from uremic toxins

Intervention type: PROCEDURE
Intervention: haemodialysis
Description: process of filtering the blood of a person whose kidneys are not working normally from uremic toxins
Study: NCT04860375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary patient care
Description: A holistic, multidisciplinary, patient-centered care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care in Sweden
Study: NCT05260853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weaning Board
Description: structured care concept